Isosinensetin Stimulates Glucagon-like Peptide-1 Secretion via Activation of hTAS2R50 and the G[sub.βγ]-Mediated Signaling Pathway

• Published in: International journal of molecular sciences 2023-02, Vol.24 (4)
• Main Authors: Lee, Seung-Hyeon, Ko, Hyun Min, Jee, Wona, Kim, Hyungsuk, Chung, Won-Seok, Jang, Hyeung-Jin
• Format: Article
• Language: English
• Subjects: Cellular signal transduction; Gastrointestinal system; Glucagon; Taste; Type 2 diabetes
• ISSN: 1422-0067
• DOI: 10.3390/ijms24043682

Bitter taste receptors (TAS2Rs) are G protein-coupled receptors localized in the taste buds of the tongue. They may also be present in non-lingual organs, including the brain, lung, kidney, and gastrointestinal (GI) tract. Recent studies on bitter taste receptor functions have suggested TAS2Rs as potential therapeutic targets. The human bitter taste receptor subtype hTAS2R50 responds to its agonist isosinensetin (ISS). Here, we demonstrated that, unlike other TAS2R agonists, isosinensetin activated hTAS2R50 as well as increased Glucagon-like peptide 1 (GLP-1) secretion through the G[sub.βγ]-mediated pathway in NCI-H716 cells. To confirm this mechanism, we showed that ISS increased intracellular Ca[sup.2+] and was suppressed by the IP[sub.3]R inhibitor 2-APB as well as the PLC inhibitor U73122, suggesting that TAS2Rs alters the physiological state of enteroendocrine L cells in a PLC-dependent manner. Furthermore, we demonstrated that ISS upregulated proglucagon mRNA and stimulated GLP-1 secretion. ISS-mediated GLP-1 secretion was suppressed in response to small interfering RNA-mediated silencing of G[sub.α]-gust and hTAS2R50 as well as 2-APB and U73122. Our findings improved the understanding of how ISS modulates GLP-1 secretion and indicates the possibility of using ISS as a therapeutic agent in the treatment of diabetes mellitus.